Orchid Pharma Ltd

Financial Performance

• Q1 FY27 revenue from operations: INR 304 crores; ~15% YoY growth.
• Q1 FY27 gross margin: 33%; Q1 FY26: ~30%.
• Q1 FY27 EBITDA: INR 25 crores; Q1 FY26: INR 10 crores.
• FY26 revenue from operations restated: INR 1,233 crores; FY25: INR 1,398 crores.
• Capex FY27: INR 750 crores for 7-ACA; Cefiderocol capex: USD 20–25 million.
• 7-ACA ramp-up: ~80% in-house, 20% third-party output.
• Cefiderocol readiness: facility ready by Dec 2026; validation and initial batches Jan–Mar 2027; DCGI waiver possible.
• Russia license Exblifep: estimated 10-year value USD 178 million.
• AMS division: Q1 EBITDA loss ~ INR 0.5 crores; revenue INR 5 crores.
• NP-NC segment quarterly revenue: INR 21 crores.
• Russia registration/launch timeline: 1.5–2 years from signing.
• 7-ACA revenue contribution expected from FY28.

Operations and Markets

• Exblifep progress in Russia valued at USD 178 million over 10 years.
• Europe volumes growth shown; Q3 FY26 up 300% QoQ, Q4 FY26 up 170%, Q1 FY27 up 50%.
• Middle East/Africa: South Africa registration complete; GCC coverage; launches delayed by regional conflict.
• 7-ACA facility ramp in Jammu chosen for cost efficiencies (GST benefits, electricity/water advantages).
• Cefepime-Enmetazobactam: domestic supply currently from in-house manufacturing; export via CMO.

Projects and Capital Expenditure

• 7-ACA capex: INR 750 crores; commissioning by March 2027.
• Cefiderocol capex: USD 20–25 million.
• Cefiderocol readiness: December 2026; first validation/batches Jan–Mar 2027.
• Russia licensing: agreement signed; registration dossier 1.5–2 years to launch.

Q&A Highlights

• 7-ACA ramp-up target: 12 months to stabilize; 80% in-house, 20% third-party use.
• Cefiderocol: supplies initially via China-based CMO; potential in-house manufacturing after site validation.
• US filings plan: new molecules planned; annual updates; limited quarterly detail.
• NZ/Global strategy: Cefide­rocol distribution network being built; GARDP discussions for distribution.

Guidance and Outlook

• No formal FY27 numeric guidance provided; expects regulated market demand to improve over 2–3 quarters.
• Longer-term outlook supported by merger synergies, product mix improvements, and capital Projects.

Meeting Details

• Date and time: August 21, 2026, 15:00 IST.
• Type and mode: group earnings call, audio conference.
• Event: Analysts/Investors Earnings Call hosted by Orchid Pharma Limited.
• Key company participant: Company Secretary & Compliance Officer.
• Purpose: discuss unaudited/limited-reviewed Q1 FY2026-27 results.
• Recording: audio recording uploaded on company's website; no video recording.

Corporate action

• Dhanuka Laboratories Ltd. amalgamated into Orchid Pharma Ltd. under the NCLT-sanctioned Scheme.

Meeting Details

• Q1FY27 results conference call for Orchid Pharma Limited on Friday, 21 August 2026 at 3:00 PM IST.
• Organizer: Systematix Institutional Equities invites participation.
• Management participants: MD, Whole Time Director, CFO.
• Mode: virtual conference call with dial-in options.
• Purpose: discuss Q1FY27 results.

Deviation details

• Mode of fund raising: Qualified Institutions Placement (QIP).
• Deviation exists and was approved by shareholders via AGM.
• Reason for deviation: business environment changes; reallocation to meet strategic needs; Jammu API postponed.
• Modified allocation objects: OBPL Jammu facility; debt repayment; Alathur API facility; general corporate purposes.
• Shareholder approval obtained via AGM.
• Monitoring agency: Care Ratings Limited.
• Audit committee comments: Annexure.
• Auditors: not applicable.
• Utilisation status: revised allocations being utilised; Jammu facility delayed.
• Major change: allocations reallocated among key objects per AGM approval.

Issue Overview

• Type of issue: QIP of equity shares.
• Total issue size; net proceeds revised; no undersubscription.
• Objectives include OBPL Jammu facility, debt repayment, Alathur API facility, and general corporate purposes.

Utilisation of Proceeds

• Utilisation aligned with revised allocation approved by AGM on Sep 20, 2025.
• Shareholder approval obtained for revised allocations.
• Means of finance changed via revised allocation; AGM approval obtained.
• No major deviation from earlier MA report.
• Statutory approvals not specified; AGM notes no further Alathur investment from QIP proceeds.
• Technical know-how: Rs 10 crore allocated; Rs 3.77 crore spent.
• OBPL Jammu facility: significant delay; commercial operations expected Feb 2027.
• Repayment of borrowings: largely allocated and utilised.
• Alathur API facility: minimal utilisation; no unutilised balance.
• Unutilised funds parked in fixed deposits; interest transferred to cash credit account.

Governance & Compliance

• Shareholder approval obtained via AGM Sep 20, 2025.
• No explicit statutory approvals listed; AGM notes no further Alathur investment.
• Delay in Jammu project; commercial operations expected Feb 2027.
• Unutilised funds parked in fixed deposits; interest credited to cash credit.

GCP

• GCP revised to 63.72 crore due to higher net proceeds.
• GCP fully utilised; completed as of Mar 31, 2025.
• Board approval obtained for revised allocations via AGM Sep 20, 2025.

Orchid Pharma Ltd board meeting scheduled; no agenda details disclosed

Meeting Details

• Date: August 01, 2026; time and venue not disclosed.

Key Agenda Items

• Allotment of Rs 10 equity shares to Dhanuka Laboratories shareholders on record date July 23, 2026 under scheme.

Other Notes

• Record date July 23, 2026 is noted for the allotment under the scheme.

Investor Roadshow Details

• Investor roadshow in Singapore to include Orchid Pharma; Mridul Dhanuka to participate as Whole Time Director.
• Dates: July 29–31, 2026; Meeting type: Group Meet; Mode: Physical.
• Location: Singapore; Schedule subject to change without prior notice.
• No unpublished price-sensitive information will be shared during the meet.
• Regulatory reference: Regulation 30, Schedule III of LODR.
• Schedule may change due to investor or company exigencies; updated notice will be provided.
• Issuer: Orchid Pharma Ltd; Scrip code 524372.

Reg 74(5) certificate

• Confirmation certificate under Reg 74(5) enclosed confirming compliance.